GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » Current Deferred Revenue

Acticor Biotech (XPAR:ALACT) Current Deferred Revenue : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Acticor Biotech's current deferred revenue for the quarter that ended in Jun. 2023 was €0.00 Mil.

Acticor Biotech Current Deferred Revenue Historical Data

The historical data trend for Acticor Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech Current Deferred Revenue Chart

Acticor Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

Acticor Biotech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only - - - - -

Acticor Biotech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acticor Biotech (XPAR:ALACT) Business Description

Traded in Other Exchanges
Address
82 Avenue du Maine, Wojo Building, Paris, FRA, 75014
Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines